

VICORE PHARMA

We have a vision to stop disease progression and restore function

- that's why we are unlocking the potential of a new class of drugs



Company in brief

Vicore is an innovative Swedish clinical-stage pharmaceutical company dedicated to creating life-changing treatments in diseases where the Angiotensin II Type 2 Receptor (AT2 receptor) has a central role in stopping and reversing disease pathology.

Location: Stockholm, Sweden with Clin Ops team in Copenhagen, Denmark

Employees ~25 FTEs. Hybrid setup

Ticker VICO, listed at Nasdaq Stockholm

Main shareholders HealthCap, Fourth Swedish National Pension Fund and HBM Healthcare Investments

Website www.vicorepharma.com

Management team

We are a diverse and experienced team driven by a shared purpose. To accomplish our ambition, we are building an organization based on trust, collaboration and challenge.

 CARL-JOHAN DALSGAARD, MD, PhD * CHIEF EXECUTIVE OFFICER <small>AstraZeneca HealthCap</small>	 CAROLINE SPEARPOINT, PhD THERAPY AREA LEAD RARE LUNG DISEASES <small>ACELEXION Pfizer</small>	 JOHAN RAUD, MD, PhD CHIEF SCIENTIFIC OFFICER <small>AstraZeneca</small>
 ELIN ROSENDAHL, MSc Pharm VP CLINICAL DEVELOPMENT <small>Pharmacia SOBI</small>	 MIKAEL NYGÅRD, PhD VP BUSINESS DEVELOPMENT <small>Hansa ECG</small>	 JESSICA SHULL, PhD * HEAD OF DIGITAL THERAPEUTICS <small>Novartis AstraZeneca</small>
 ROHIT BATTÀ, MBBS, MRCP, MFPM * CHIEF MEDICAL OFFICER <small>Novartis</small>	 HANS JEPSSON, PhD CHIEF FINANCIAL OFFICER <small>Novartis AstraZeneca</small>	 STINE FURBO HEAD OF CMC <small>ALIK</small>
 NINA CARLÉN CHIEF ADMINISTRATIVE OFFICER <small>Novartis</small>	 JOHANNA GRÅNS, PhD PROGRAM DIRECTOR, EARLY DEVELOPMENT <small>Novartis</small>	 ÅSA MAGNUSSON * CHIEF COMMERCIAL OFFICER <small>ACELEXION AstraZeneca</small>

*Attending RIS


Board Members

JACOB GUNTERBERG	Chairman. Former partner at HealthCap with extensive experience from venture capital investment operations and corporate finance in life science. Extensive experience as board member in both private and publicly traded companies.
ELISABETH BJÖRK	More than 15 years of experience from clinical practice, academic research and management of drug development in big pharma as well as global commercial strategy and implementation across regions and therapy areas. Currently leading global late-stage development activities in Cardiovascular, Renal & Metabolism at AstraZeneca.
MICHAEL BUSCHLE	More than 25 years of experience in basic research as well as biotech and pharma R&D. Experience at mid-size pharma and biotech companies including in- and out-licensing of assets as well as from C-level positions. Longstanding experience in investment consulting and financing and currently a consultant within the biotech industry for HBM Partners AG.
HEIDI HUNTER	More than 25 years of experience from leading positions in different roles within pharmaceutical development and commercialization. Leadership experience spans alliance management, investment risk mitigation, global clinical and commercial management, new business strategy development, product launch, and business sustainability.
MAARTEN KRAAN	25 years biopharma industry experience, including managerial roles at AstraZeneca, Pierre Fabre and Hoffman-La Roche. Currently CMO at AM-Pharma and a board member of Toleranzia AB and CDS GmbH.
HANS SCHIKAN	25 years management experience in global pharmaceuticals (CEO of Prosenza & leading roles at Genzyme and Organon). Extensive board work in listed life science companies (Hansa Biopharma, Wilson Tx (acquired by Alexion), SOBI, Asceneuron, InterRNA and Therachon (acquired by Pfizer)).


Contact: Åsa Magnusson, asa.magnusson@vicorepharma.com

Patient focused asset development in pulmonary fibrosis

C21 as a first in class ATRAG (Angiotensin II Type 2 Receptor Agonist)



Unprecedented clinical data with C21 in IPF – AIR phase 2 trial



Almee™ is based on patient centric design - serving a clear unmet need - anxiety in patients with pulmonary fibrosis




Diversified pipeline with key readouts in the next year

Indication	Program	Preclinical	Phase 1	Phase 2	Phase 3	Comments
IPF	C21	██████████	██████████			Final data phase 2a, Q4 2023. Phase 2b trial preparations during 2023
PAH	C21	██████████	██████████			Proof of principle study on endothelial function planned during 2023
Anxiety in pulmonary fibrosis	Almee™ DTx	██████████	██████████			Read-out pivotal study in Q4 2023
IPF cough	Inhaled IMID	██████████				Preclinical formulation
Cardiorenal	C106	██████████	██████████			Phase 1 data, H1 2023
Multiple indications	C103, C111, C112	██████████				Preclinical studies


ATRAG - preclinical data support use in several diseases

Target engagement

Autoradiography of human lung tissue



Ref: Vicore data on file




Significant and specific C21 receptor binding

Preclinical data

C21 treatment highly effective, consistent results across models:

Parameter	Sugen-Hypoxia	Bleomycin	Monocrotaline
Lung Fibrosis	↓	↓	↓
Muscularisation of pulmonary vessels	↓	↓	↓
Vascular and cardiac remodeling	↓	↓	↓
Pulmonary hypertension	↓	↓	↓
Cardiac function	↑	↑	↑


C21 normalizes collagen content and reduces diastolic PAP in the Sugen-model:



C21 reduces fibrosis, collagen content and reverses vascular remodeling

Ref: Bruce et al. 2015, Rathinasabapathy et al. 2018, Tornling et al. 2023

Fibrosis reduction in humans



Ref: Vicore data on file

Dose-dependent decrease of myfibroblast activation and fibrosis markers

Vicore – strong presence at the ATS congress

C21

- AIR phase 2a in IPF – updated interim analysis
- Sunday, May 21st at 2:15 - 4:15 pm (Prof Toby Maher)
- A99 mini symposium: Clinical trials in chronic lung disease

Almee™

- COMPANION pilot study in anxiety associated with IPF
- Monday, May 22nd at 9:00 - 11:00 am (Prof Maureen Horton)
- B17 mini symposium: Emerging data on disease and symptom-based therapeutics for IPF

ATRAGs

- Development of ATRAGs for Treatment of Pulmonary Fibrosis and Pulmonary Hypertension
- Wednesday, May 24th at 8:00 - 10:00 am (Johan Raud/Cecilia Ganslandt)
- D29 poster discussion session: Translational research in IPF

Thank you to patients and their caregivers for supporting our trials. We recognize your contribution to research.

